multiple sclerosis
MONDO:0005301
A progressive autoimmune disorder affecting the central nervous system resulting in demyelination. Patients develop physical and cognitive impairments that correspond with the affected nerve fibers.
Research intelligence
Directly mapped studies only · unique clinical trialsCurrent registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.
Medications under investigation
Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.
MONDO disease family
Recruiting studies by city
Trial status
Trial phase
Study start year
Investigated drug interventions
Multiple sclerosis
Multiple sclerosis (MS) is a chronic and neurodegenerative autoimmune disease in which the immune system attacks myelin, the insulating cover of nerve cells, causing damage to the central nervous system. This impairs the nervous system's ability to transmit signals. Symptoms include double vision, vision loss, eye pain, muscle weakness, loss of coordination, as well as cognitive issues like problems with memory. MS may be a rare complication of an Epstein-Barr virus (EBV) infection. Genetics and environmental factors like exposure to sunlight also impact the risk of MS. MS can be diagnosed based on symptoms, MRI scans, and sometimes a lumbar puncture to investigate spinal fluid. There is no cure for MS. Current treatments aim to manage symptoms during acute flares and prevent further attacks with disease-modifying therapies. With effective treatment, it is possible to reduce attacks strongly, but the disease progress is not fully stopped. In addition, symptoms of MS like balance issues can be managed with drugs and with non-drug treatments (e.g. physical therapy). On average, life expectancy is slightly lower than normal. In 2024, about 3.1 million people were affected by MS globally, with rates much higher further from the equator. The disease usually begins between the ages of 20 and 40 and is almost three times more common in women than in men. MS was first described in 1868 by French neurologist Jean-Martin Charcot.
Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.Clinical trials
40 shownDrugs being studied
Research locations
Leading sponsors
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.